Press Releases

VALHALLA, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- FUJIFILM North America Corporation, Optical Devices Division, will unveil a fully immersive 360° booth experience -- with the walls, floor, and ceiling of the space entirely comprised of visual projections from a grouping of FUJIFILM FP-Z8000 Projectors (FP-Z8000) -- at InfoComm 2024, to be held June 12–14, 2024 in Las Vegas at Fujifilm’s booth W2965.

Delivering this dynamic immersive content will be a dozen... (continue reading...)

AMSTERDAM, June 6, 2024 /PRNewswire/ -- A groundbreaking generative AI copilot plugin, launched by Lucinity at Money2020 Europe, delivers immediate ROI. The copilot plugin is system-agnostic, acting as one central copilot that can be used on top of all web-based enterprise applications, pulling data from any system including Customer Relationship Management (CRM) systems, case management systems, third-party vendors, and Excel documents.

... (continue reading...)

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Xineoh Technologies Inc. ("Xineoh" or the "Company"), at the forefront of AI-driven insights, announces a leadership transition. Hans Hawinkels, who has served as Chairman since 2021, has stepped down from the role and as a director. The board and the entire Xineoh team extend their heartfelt gratitude to Hans for his immense contributions in establishing Xineoh as a trailblazer in AI technology.

During his... (continue reading...)

VANCOUVER, BC / ACCESSWIRE / June 6, 2024 / Apex Critical Metals Corp. (CSE:APXC)(OTCQB:APXCF) ("Apex" or the "Company"), is pleased to announce that the Company has entered into an Earn-In Option Agreement ("the Agreement") with Discovery Lithium inc. ("Discovery Lithium") and DG Resource Management LTD. ("DG Resource") on the West James Bay property portfolio. The portfolio includes the Mantle, Cirrus East, Cirrus West, Neptune, Alto, Opus and Bruce Lake projects... (continue reading...)

CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value.

2023... (continue reading...)